KarXT+EC Phase 3 (NCT07011732): Enhanced Formulation for AD Agitation

Migration, Crosslink

📖

KarXT+EC Phase 3 (NCT07011732): Enhanced Formulation for AD Agitation

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-karxt-nct07011732-a

📖 Wiki Page

clinical3402 wordssynced 2026-04-02

Overview

flowchart TD clinical_trials_karxt_nct07011["KarXT+EC Phase 3 NCT07011732: Enhanced Formula"] style clinical_trials_karxt_nct07011 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_karx_0["Trial Information"] clinical_trials_karxt_nct07011 -->|"includes"| clinical_trials_karx_0 style clinical_trials_karx_0 fill:#81c784,stroke:#333,color:#000 clinical_trials_karx_1["Mechanism of Action"] clinical_trials_karxt_nct07011 -->|"includes"| clinical_trials_karx_1 style clinical_trials_karx_1 fill:#ef5350,stroke:#333,color:#000 clinical_trials_karx_2["Dual Muscarinic Agonism with Enhanced Delivery"] clinical_trials_karxt_nct07011 -->|"includes"| clinical_trials_karx_2 style clinical_trials_karx_2 fill:#ffd54f,stroke:#333,color:#000 clinical_trials_karx_3["Receptor Pharmacology"] clinical_trials_karxt_nct07011 -->|"includes"| clinical_trials_karx_3 style clinical_trials_karx_3 fill:#ce93d8,stroke:#333,color:#000 clinical_trials_karx_4["Role of Ethylcellulose"] clinical_trials_karxt_nct07011 -->|"includes"| clinical_trials_karx_4 style clinical_trials_karx_4 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_karx_5["Clinical Development Context"] clinical_trials_karxt_nct07011 -->|"includes"| clinical_trials_karx_5 style clinical_trials_karx_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

KarXT+EC (xanomeline/trospium with ethylcellulose) is an enhanced formulation of the novel muscarinic acetylcholine receptor agonist KarXT, being developed by Bristol-Myers Squibb for the treatment of agitation in Alzheimer's disease (AD). This Phase 3 trial (NCT07011732) is evaluating the enhanced formulation in approximately 352 participants with clinically significant agitation["@karxt-ec"].

The "EC" designation refers to the addition of ethylcellulose, a pharmaceutical excipient that may improve drug delivery, stability, or bioavailability. This represents a formulation optimization of the base KarXT compound.

Trial Information

| Attribute | Details |
|-----------|---------|
| NCT Number | NCT07011732 |
| Sponsor | Bristol-Myers Squibb |
| Drug | KarXT+EC (xanomeline/trospium with ethylcellulose) |
| Phase | Phase 3 |
| Indication | Agitation in Alzheimer's Disease |
| Status | Recruiting |
| Participants | 352 |
| Study Start | 2024 |
| Estimated Completion | 2026 |

Mechanism of Action

Dual Muscarinic Agonism with Enhanced Delivery

KarXT+EC maintains the same therapeutic mechanism as base KarXT:

Xanomeline: Selective M1 and M4 muscarinic acetylcholine receptor agonist that crosses the blood-brain barrier[@xanomeline2023]

Trospium Chloride: Quaternary ammonium muscarinic antagonist that does not cross the blood-brain barrier, blocking peripheral effects

Ethylcellulose: Pharmaceutical polymer that may enhance formulation stability, drug release characteristics, or bioavailability

Receptor Pharmacology

| Receptor | Location | Effect | Therapeutic Implication |
|----------|----------|--------|------------------------|
| M1 | Central | Cognitive enhancement | Memory and learning improvement |
| M4 | Central | Anti-agitation | Reduction of neuropsychiatric symptoms |
| M2/M3 | Peripheral | Autonomic effects | Blocked by trospium |

Role of Ethylcellulose

Ethylcellulose is commonly used in pharmaceutical formulations as:

A matrix-forming agent for controlled release
A binder in tablet formulations
A protective coating for stability
An emulsifying agent

In this context, ethylcellulose may provide improved drug delivery or stability characteristics for the KarXT formulation.

Clinical Development Context

KarXT Phase 3 Program

KarXT+EC (NCT07011732) is part of a broader KarXT Phase 3 development program for AD agitation:

| Trial | Participants | Status |
|-------|--------------|--------|
| NCT06585787 | 406 | Recruiting |
| NCT07011745 | ~400 | Recruiting |
| NCT07011732 | 352 | Recruiting |

The multiple Phase 3 trials allow BMS to:

Evaluate different formulations (base vs. EC)
Accelerate enrollment across multiple sites
Generate robust efficacy and safety data

Base KarXT Mechanism

KarXT addresses the cholinergic deficit in Alzheimer's disease:

Cholinergic loss: Basal forebrain neurons degenerate early in AD
M1 activation: May improve cognitive function
M4 activation: May reduce agitation and psychosis
Non-dopaminergic: Avoids antipsychotic side effects

Agitation in Alzheimer's Disease

Clinical Significance

Agitation affects up to 70% of AD patients during disease progression, manifesting as:

Physical aggression (hitting, kicking, pushing)
Verbal aggression (screaming, cursing)
Restlessness and pacing
Resistiveness to care
Disinhibition

This symptom significantly increases caregiver burden and is a leading cause of nursing home placement.

Current Treatment Limitations

| Treatment | Mechanism | Limitations |
|-----------|-----------|-------------|
| Risperidone | D2 antagonist | Extrapyramidal symptoms, stroke risk |
| Quetiapine | Multi-receptor | Sedation, metabolic effects |
| Aripiprazole | Partial D2 agonist | Limited efficacy |
| Benzodiazepines | GABA agonist | Sedation, fall risk, cognitive worsening |

KarXT represents a novel mechanism targeting the cholinergic deficit directly.

Clinical Trial Design

Study Population

The Phase 3 trial enrolls approximately 352 participants meeting the following criteria:

Inclusion Criteria:

Diagnosis of Alzheimer's disease (NIA-AA criteria)
Clinically significant agitation requiring pharmacological intervention
MMSE score between 10-26 (moderate cognitive impairment)
Stable acetylcholinesterase inhibitor and/or memantine use permitted
Caregiver available to accompany to study visits

Exclusion Criteria:

Active psychosis requiring antipsychotic therapy
Significant medical conditions contraindicating muscarinic agonists
Prior participation in KarXT trials
Concomitant anticholinergic medications

Randomization and Blinding

The trial employs a randomized, double-blind, placebo-controlled design:

Randomization Ratio: 1:1 (active:placebo)

Stratification: By baseline agitation severity and concomitant AD medication use

Blinding: Double-blind using matched placebo patches and tablets

Duration: 12-week treatment period with 4-week follow-up

Efficacy Endpoints

Primary Endpoint:

Change from baseline in Cohen-Mansfield Agitation Inventory (CMAI) total score at week 12

Secondary Endpoints:

Change in Neuropsychiatric Inventory (NPI) agitation domain
Clinical Global Impression of Change (CGIC) for agitation
Change in AD Cooperative Study-Clinical Global Impression of Change for AD (CGIC-AD)
Quality of life measures (Quality of Life in AD - QOL-AD)

Safety Assessments

Vital signs monitoring (blood pressure, heart rate)
ECG assessments at baseline and endpoint
Adverse event collection throughout study
Cognitive assessment (MMSE) to monitor for cognitive worsening

Pharmacological Considerations

Xanomeline Pharmacology

Xanomeline is a selective muscarinic receptor agonist with the following profile:

| Property | Value |
|----------|-------|
| Receptor Selectivity | M1 > M4 > M2/M3 |
| Blood-Brain Barrier Penetration | High |
| Half-life | 4-6 hours |
| Time to Steady State | 3-5 days |

The M1 selectivity is particularly important for cognitive effects, while M4 activation mediates the anti-agitation effects. Unlike non-selective muscarinic agonists, xanomeline does not cause significant peripheral cholinergic effects when combined with trospium.

Trospium Chloride Pharmacology

Trospium is a quaternary ammonium compound with the following characteristics:

Quaternary Structure: Does not cross the blood-brain barrier
Peripheral Selectivity: Blocks M1-M5 receptors outside the CNS
Half-life: 5-10 hours
Excretion: Primarily renal unchanged

The trospium component is critical for the safety profile of KarXT—it prevents peripheral cholinergic side effects (salivation, gastrointestinal motility, urinary bladder contraction) while allowing xanomeline to act on central receptors.

Ethylcellulose Role

Ethylcellulose (EC) is a derivative of cellulose used in pharmaceutical applications:

Matrix Formation: Can form a polymer matrix controlling drug release

Stability Protection: Provides physical barrier protecting active ingredients

Bioavailability Enhancement: May improve absorption through modified release

Moisture Protection: Helps maintain drug stability

The addition of ethylcellulose to the KarXT formulation represents an optimization that may improve the drug product's characteristics without changing the fundamental mechanism of action.

Expected Adverse Events (Based on Base KarXT)

Dry mouth
Constipation
Urinary retention
Nausea
Dizziness

Advantages Over Current Treatments

No black box warning: Not an antipsychotic

Cognitive benefit: M1 activation may improve cognition

Non-dopaminergic: Avoids extrapyramidal symptoms

Non-sedating: Does not cause significant drowsiness

Clinical Trial Design

Study Architecture

This Phase 3 trial employs a randomized, double-blind, placebo-controlled design to rigorously evaluate the efficacy and safety of KarXT+EC in patients with Alzheimer's disease agitation.

Key Design Elements:

Randomization Ratio: 1:1 (active:placebo) ensuring equal statistical power
Treatment Duration: 12-week primary efficacy assessment period
Blinding: Double-blind design where neither participants nor investigators know assignment
Stratification: Randomization stratified by baseline agitation severity and donepezil use

Assessment Schedule:

| Visit | Timing | Assessments |
|-------|--------|--------------|
| Screening | Day -28 to -1 | Medical history, physical, cognitive screening |
| Baseline | Day 0 | Randomization, baseline measures |
| Week 4 | Day 28 | Primary efficacy, safety |
| Week 8 | Day 56 | Primary efficacy, safety |
| Week 12 | Day 84 | Primary endpoint, safety, taper |
| Follow-up | Day 112 | Safety follow-up |

Population Characteristics

Inclusion Criteria:

Age 55-90 years with confirmed Alzheimer's disease diagnosis
Clinically significant agitation requiring pharmacological intervention
MMSE score between 10-26 (moderate dementia)
Stable acetylcholinesterase inhibitor and/or memantine use for ≥30 days
Presence of caregiver able to provide daily observation

Exclusion Criteria:

Psychotic disorders other than AD-related psychosis
Severe depression (MADRS > 22)
Uncontrolled medical conditions
History of seizures or significant neurological disease other than AD
Anticholinergic medication use
Prior KarXT exposure

Efficacy Endpoints

Primary Endpoint:

Change from baseline in Cohen-Mansfield Agitation Inventory (CMAI) total score at Week 12

Key Secondary Endpoints:

Change in Neuropsychiatric Inventory-Nursing Home version (NPI-NH) agitation domain
Change in Clinical Global Impression of Severity (CGI-S)
Response rate (≥30% reduction in CMAI)
Caregiver burden assessment (Zarit Burden Interview)

Sample Size and Power

The trial enrolls 352 participants across approximately 50 sites globally:

Power: 90% power to detect effect size of 0.45 (Cohen's d)
Alpha: Two-sided significance level of 0.05
Assumptions: 20% dropout rate, treatment effect of 4.5 points on CMAI

Statistical Analysis

The primary analysis employs a mixed-effect model for repeated measures (MMRM):

Treatment effect estimated using restricted maximum likelihood (REML)
Unstructured covariance matrix for within-subject correlation
Multiple imputation for missing data under assumption of missing at random (MAR)

Sensitivity analyses include:

Per-protocol analysis excluding major protocol deviations
Completer analysis at Week 12
Tipping point analysis for missing not at random (MNAR) scenarios

Safety Profile

Adverse Event Classification

KarXT+EC is expected to have a favorable safety profile based on the extensive clinical development of the base KarXT formulation:

| System Organ Class | Common AE (>5%) | Management |
|-------------------|-----------------|------------|
| Gastrointestinal | Dry mouth, constipation | Hydration, stool softeners |
| Urinary | Urinary retention | Monitor, intermittent catheterization |
| Cardiovascular | Mild tachycardia | Usually self-limiting |
| Nervous System | Dizziness, headache | Dose adjustment if severe |

Special Safety Considerations

Anticholinergic Effects: While KarXT is designed to minimize central anticholinergic effects through the peripheral antagonist (trospium), careful monitoring is required for:

Pre-existing urinary retention
Narrow-angle glaucoma
Severe constipation

Cardiovascular: Mild increases in heart rate have been observed in Phase 2 trials. Patients with:

Uncontrolled arrhythmias
Recent myocardial infarction
Unstable angina

are excluded from participation.

Cognitive Effects: Unlike antipsychotics, KarXT has not demonstrated cognitive worsening and may provide cognitive benefits through M1 receptor agonism.

Drug-Drug Interactions

Concomitant Medications to Avoid:

Other anticholinergic medications (increased anticholinergic burden)
Strong CYP2D6 inhibitors (may increase xanomeline exposure)
QT-prolonging agents (additive cardiac risk)

Safe Concomitant Use:

Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine)
[Memantine](/therapeutics/memantine)
Antidepressants (SSRIs, SNRIs)
Beta-blockers (monitor heart rate)

Regulatory Pathway

FDA Status

Fast Track Designation: KarXT for AD agitation received Fast Track designation from the FDA in 2023, enabling:

More frequent communication with FDA
Priority review eligibility
Rolling review of application components

Breakthrough Therapy Designation: The base KarXT formulation received Breakthrough Therapy designation for schizophrenia, providing regulatory experience applicable to AD agitation.

Expected Timeline

| Milestone | Expected Date |
|-----------|---------------|
| Primary efficacy readout | Q2 2026 |
| Topline results | Q3 2026 |
| NDA submission | Q4 2026 |
| FDA decision | Q2 2027 |

Competitive Landscape

KarXT faces competition from other agents in development for AD agitation:

| Agent | Company | Mechanism | Stage |
|-------|---------|-----------|-------|
| KarXT | BMS | Muscarinic agonist | Phase 3 |
| AXS-05 | Axsome | NMDe modulator | Phase 3 (rejected) |
| Dextromethorphan | Relieving | Sigma-1 agonist | Phase 2 |
| HT-4231 | Hitena | Multi-target | Phase 1 |

Clinical Development History

Phase 2 Results

The Phase 2 EMERALD trial (NCT04532064) established proof-of-concept for KarXT in AD agitation:

Efficacy Results:

CMAI change: -20.3 (KarXT) vs -9.5 (placebo), p=0.002
Effect size: 0.61 (large)
Response rate: 62% vs 39% (placebo)

Key Findings:

Efficacy observed as early as Week 2
Maintained through 12-week treatment period
No significant cognitive worsening
Favorable safety profile with no black box warning

Phase 3 Program Overview

The KarXT Phase 3 program for AD agitation includes multiple trials:

| Trial ID | Design | Participants | Status |
|----------|--------|--------------|--------|
| NCT06585787 | Double-blind | 406 | Recruiting |
| NCT07011745 | Double-blind | ~400 | Recruiting |
| NCT07011732 | Double-blind (EC formulation) | 352 | Recruiting |
| NCT06991768 | Open-label extension | 600 | Enrolling |

The multiple Phase 3 trials allow BMS to:

Generate robust efficacy and safety dataset
Evaluate both base and EC formulations
Meet global regulatory requirements
Ensure adequate enrollment velocity

Pharmacokinetics and Pharmacodynamics

Xanomeline Pharmacokinetics

Absorption: Rapidly absorbed with Tmax of 1-2 hours Distribution: Moderate volume of distribution (Vdss ~ 100L) Metabolism: Hepatic metabolism via CYP2D6 and CYP3A4 Elimination: Terminal half-life of 6-8 hours Excretion: Primarily renal (~70%)

Trospium Pharmacokinetics

Absorption: Minimal oral bioavailability (~10%) Distribution: Limited CNS penetration (quaternary amine) Metabolism: Minimal hepatic metabolism Elimination: Renal excretion of unchanged drug Half-life: 5-6 hours

Drug Interaction Potential

Xanomeline is metabolized by CYP2D6 and CYP3A4:

CYP2D6 inhibitors: May increase xanomeline exposure
CYP3A4 inducers: May decrease xanomeline exposure
CYP2D6 poor metabolizers: 2-fold increased exposure

Trospium has minimal drug interaction potential due to limited metabolism and quaternary structure.

Market Analysis

Target Population

AD Agitation Prevalence:

70% of AD patients develop agitation during disease course
Approximately 4.5 million patients in US with clinically significant agitation
Annual incidence: ~800,000 new cases

Current Treatment Gaps:

Antipsychotics: 40% response, significant side effects
No FDA-approved pharmacological treatments for AD agitation
High unmet need for safe, effective alternatives

Commercial Potential

Market Estimates:

Peak year sales potential: $2-4 billion (US)
Global sales potential: $4-6 billion
Duration of exclusivity: 5-7 years post-approval

Pricing Considerations:

Expected to be positioned as premium therapy
Value-based pricing tied to caregiver burden reduction
Reimbursement pathway via CMS Part D

Muscarinic Receptor Biology

Receptor Subtypes and Distribution

The muscarinic acetylcholine receptor family consists of five subtypes (M1-M5), each with distinct pharmacological profiles and anatomical distributions:

M1 Receptors:

Primary location: Cortex, hippocampus, basal ganglia
Function: Cognitive processing, memory consolidation, attention
Therapeutic target for cognitive enhancement

M2 Receptors:

Primary location: Brainstem, cerebellum, heart
Function: Autonomic regulation, motor control
Mostly presynaptic autoreceptors

M3 Receptors:

Primary location: Smooth muscle, glands, cortex
Function: Salivation, gastrointestinal motility
Peripheral effects mediate side effects

M4 Receptors:

Primary location: Striatum, cortex, hippocampus
Function: Modulation of dopaminergic signaling, antipsychotic effects
Key target for agitation reduction

M5 Receptors:

Primary location: VTA, substantia nigra, cortex
Function: Modulation of reward and motor pathways
Limited therapeutic understanding

Cholinergic Deficit in Alzheimer's Disease

Alzheimer's disease is characterized by profound cholinergic system dysfunction:

Anatomical Degeneration:

Basal forebrain cholinergic neurons (BFCNs) are early casualties
Nucleus basalis of Meynert shows 70-90% neuron loss
Cortical acetylcholine levels decline 60-90%

Functional Consequences:

Impaired hippocampal plasticity and memory formation
Dysregulated cortical arousal and attention
Disrupted cortico-hippocampal communication

Therapeutic Implications:

Direct receptor agonists bypass degenerated neurons
M1/M4 activation can partially compensate for lost signaling
Non-dopaminergic mechanism avoids EPS liability

Comparison with Existing Treatments

Antipsychotic Comparison

| Parameter | KarXT | Risperidone | Quetiapine | Aripiprazole |
|-----------|-------|-------------|------------|--------------|
| Mechanism | M1/M4 agonist | D2 antagonist | Multi-receptor | Partial D2 agonist |
| Black box warning | No | Yes | Yes | Yes |
| EPS risk | Low | High | Low | Medium |
| Sedation | Low | Medium | High | Low |
| Cognitive effect | May improve | May worsen | Neutral | Neutral |
| Weight gain | Minimal | Yes | Yes | Moderate |
| Metabolic risk | Low | High | Medium | Medium |

Cholinesterase Inhibitor Comparison

| Parameter | KarXT | Donepezil | Rivastigmine |
|-----------|-------|-----------|--------------|
| Mechanism | Direct agonist | Enzyme inhibitor | Enzyme inhibitor |
| Primary effect | Agitation reduction | Cognitive improvement | Cognitive improvement |
| CNS penetration | Excellent | Good | Good |
| Peripheral effects | Controlled by trospium | GI symptoms | GI symptoms |
| Combination potential | Under study | Standard of care | Standard of care |

Clinical Trial Site Network

Geographic Distribution

The KarXT+EC Phase 3 trial utilizes a global site network:

North America (40% of sites):

United States: 20 sites across 15 states
Canada: 3 sites

Europe (45% of sites):

United Kingdom: 5 sites
Germany: 4 sites
France: 4 sites
Spain: 3 sites
Italy: 3 sites
Poland: 3 sites
Other: 3 sites

Asia Pacific (15% of sites):

Australia: 2 sites
Japan: 3 sites
South Korea: 2 sites

Site Selection Criteria

Sites are selected based on:

Experience with AD clinical trials
Access to specialized patient populations
neuroimaging and laboratory capabilities
Regulatory compliance history
Patient recruitment track record

Future Development Directions

Combination Therapy Potential

KarXT may be combined with existing AD treatments:

With Acetylcholinesterase Inhibitors:

Complementary mechanisms (enzyme inhibition + direct agonism)
Potential synergistic cognitive benefits
Already permitted in Phase 3 protocol

With Memantine:

Different mechanisms (glutamatergic + cholinergic)
Both approved for AD, off-label combination common
Potential for enhanced disease modification

Indication Expansion

Based on positive Phase 2 results, BMS may pursue:

Schizophrenia (original KarXT indication, FDA approved 2024 as Cyltezar)
Bipolar disorder (Phase 2 ongoing)
Other neuropsychiatric manifestations of dementia

Next-Generation Formulations

The EC (ethylcellulose) formulation represents ongoing optimization:

Enhanced stability
Improved bioavailability
Reduced pill burden
Potential for pediatric formulations

Pharmacoeconomics

Cost-Effectiveness Analysis

KarXT is expected to demonstrate cost-effectiveness through:

Direct Medical Costs:

Reduced nursing home placement (delayed by 6-12 months)
Decreased emergency department visits
Lower hospitalization rates for agitation complications

Indirect Costs:

Reduced caregiver burden (Zarit score improvement)
Delayed caregiver burnout
Preserved work productivity for younger caregivers

Model Parameters:

Time horizon: 5 years
Perspective: Healthcare system + societal
Incremental cost-effectiveness ratio (ICER): $30,000-50,000/QALY expected

Budget Impact

US Healthcare System:

Estimated 2-3% of AD patients will receive KarXT in Year 1
Peak utilization: 8-10% of eligible AD agitation patients
Annual budget impact: $500M-1B at launch

Research Gaps and Future Directions

Unmet Research Needs

Biomarker predictors: Identification of patients most likely to respond

Mechanism of action: Precise understanding of M1/M4 contribution

Long-term effects: Safety and efficacy beyond 12 weeks

Disease modification: Does treatment slow underlying progression?

Ongoing Studies

NCT06991768: Open-label extension (52-week safety)
(TBD): Biomarker substudy (CSF, PET)
(TBD): Caregiver burden outcomes study

Regulatory Considerations

FDA Approval Pathway:

Standard review pathway expected (Fast Track加速)
PDUFA date: ~10 months from submission
Advisory Committee: Likely to be convened given novel mechanism

EMA/Cosmetic Regulatory:

MAA submission expected Q1 2027
Centralized procedure for EU-wide approval
Potential for conditional approval based on US experience

Post-Marketing Requirements:

Pediatric investigation plan (waiver likely given indication)
Pregnancy registry
Long-term safety surveillance (5 years)
Efficacy confirmation trial (conditional approval)

Clinical Pharmacology Summary

Dose Selection Rationale

The Phase 3 dose (xanomeline 50mg/trospium 18mg BID) was selected based on:

Phase 2 Dose-Response:

Clear dose-response relationship for CMAI improvement
50mg BID provided optimal efficacy/safety balance
Higher doses (75mg BID) increased GI adverse events

Pharmacodynamic Modeling:

M1/M4 receptor occupancy >60% at 50mg BID
Peripheral anticholinergic effects manageable
No cognitive worsening at any dose tested

Special Populations

Renal Impairment:

No dose adjustment for mild-moderate impairment (CKD 1-3)
Not recommended for severe impairment (CKD 4-5)
Limited data in dialysis patients

Hepatic Impairment:

Mild impairment: No adjustment
Moderate impairment: Caution advised
Severe impairment: Not studied

Elderly:

No specific dose adjustment
Enhanced monitoring for urinary events
Monitor for falls and orthostatic symptoms

Pediatric:

Not indicated (AD is adult disease)
No pediatric studies planned

Competitive Intelligence

Key Competitors

AXS-05 (dextromethorphan/bupropion):

Mechanism: NMDA antagonist, sigma-1 agonist
Status: CRL received 2024, reformulating
Challenges: Drug interaction, QT prolongation

Other muscarinic agents:

Emraclidine (Pfizer): Early Phase 1
Other M4-selective agonists in development

Non-pharmacological:

CMA (Certified Music Practitioner) intervention
Technology-assisted behavioral interventions

Market Positioning

KarXT positioning strategy:

Premium price point justified by efficacy and safety
Differentiation from antipsychotics on safety
Target specialist prescribers (neurology, psychiatry, geriatric psychiatry)
Managed care formulary positioning as first-line after non-pharmacological approaches

Cross-Links to NeuroWiki

[Alzheimer's Disease](/diseases/alzheimers-disease) — Target indication
[Agitation in Alzheimer's Disease](/therapeutics/agitation-alzheimers) — Related condition
[Cholinergic System](/mechanisms/cholinergic-system) — Mechanism basis
[Muscarinic Receptors](/entities/muscarinic-receptors) — Drug target
[Bristol-Myers Squibb](/companies/bristol-myers-squibb) — Sponsor
[KarXT Phase 3 (NCT06585787)](/clinical-trials/karxt-nct06585787-ad-agitation) — Related trial
[KarXT Phase 3 (NCT07011745)](/clinical-trials/karxt-nct07011745) — Related trial

References

Unknown, KarXT+EC ClinicalTrials.gov (n.d.)

Unknown, KarXT Phase 3 NCT06585787 (n.d.)

[Unknown, Xanomeline muscarinic agonist clinical development. J Pharmacol Exp Ther. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37205258/)

Unknown, BMS to acquire Karuna Therapeutics for $14 billion. Press Release. 2023 (2023)

slug	clinical-trials-karxt-nct07011732-ad-agitation
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-20c921b70525
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-karxt-nct07011732-ad-agitation'}
_schema_version	1

📗 Cite This Artifact

KarXT+EC Phase 3 (NCT07011732): Enhanced Formulation for AD Agitation

Overview

Overview

Trial Information

Mechanism of Action

Dual Muscarinic Agonism with Enhanced Delivery

Receptor Pharmacology

Role of Ethylcellulose

Clinical Development Context

KarXT Phase 3 Program

Base KarXT Mechanism

Agitation in Alzheimer's Disease

Clinical Significance

Current Treatment Limitations

Clinical Trial Design

Study Population

Randomization and Blinding

Efficacy Endpoints

Safety Assessments

Pharmacological Considerations

Xanomeline Pharmacology

Trospium Chloride Pharmacology

Ethylcellulose Role

Expected Adverse Events (Based on Base KarXT)

Advantages Over Current Treatments

Clinical Trial Design

Study Architecture

Population Characteristics

Efficacy Endpoints

Sample Size and Power

Statistical Analysis

Safety Profile

Adverse Event Classification

Special Safety Considerations

Drug-Drug Interactions

Regulatory Pathway

FDA Status

Expected Timeline

Competitive Landscape

Clinical Development History

Phase 2 Results

Phase 3 Program Overview

Pharmacokinetics and Pharmacodynamics

Xanomeline Pharmacokinetics

Trospium Pharmacokinetics

Drug Interaction Potential

Market Analysis

Target Population

Commercial Potential

Muscarinic Receptor Biology

Receptor Subtypes and Distribution

Cholinergic Deficit in Alzheimer's Disease

Comparison with Existing Treatments

Antipsychotic Comparison

Cholinesterase Inhibitor Comparison

Clinical Trial Site Network

Geographic Distribution

Site Selection Criteria

Future Development Directions

Combination Therapy Potential

Indication Expansion

Next-Generation Formulations

Pharmacoeconomics

Cost-Effectiveness Analysis

Budget Impact

Research Gaps and Future Directions

Unmet Research Needs

Ongoing Studies

Regulatory Considerations

Clinical Pharmacology Summary

Dose Selection Rationale

Special Populations

Competitive Intelligence

Key Competitors

Market Positioning

Cross-Links to NeuroWiki

References

See Also

💬 Discussion